Sesen Bio director Jane Pritchett Henderson resigns from Board, becomes CEO Advisor

Carisma Therapeutics Inc.

Jane Pritchett Henderson resigned from Sesen Bio's Board effective Nov. 22, 2021, to focus on other roles including CFO at Adagio Therapeutics.
She transitions to CEO Advisor role; no disagreement with company policies or operations.
Jason Keyes named Chair of Audit Committee; Board Chair Jay Duker assumes Chair of Compensation Committee.
Board now has six directors, all independent except CEO Thomas Cannell.
Henderson joins five other executives already serving as CEO Advisors.

item 5.02 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Departed

Jane Pritchett Henderson

Director

CARM · Carisma Therapeutics Inc.

Effective: 2021-11-22
Filed: November 23, 2021, 6:59 PM ET

Jane Pritchett Henderson resigned from the Company’s Board of Directors (the “Board”) effective November 22, 2021

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Jane Pritchett Henderson resigned as Director at Carisma Therapeutics Inc..

Action: resigned
Role: Director

Exact text from the filing

Jane Pritchett Henderson resigned from the Company’s Board of Directors (the “Board”) effective November 22, 2021

View on SEC.gov

Carisma Therapeutics Inc. filing history →

Source: SEC EDGAR

accession 0001485003-21-000226

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.